Plejuv

Plejuv: Biphasic HA Filler for Comprehensive Correction from Deep Volumization to Superficial Hydration

Plejuv , manufactured by **Hugel Inc.** (South Korea), is a **biphasic hyaluronic acid (HA) dermal filler** specifically designed for **versatile facial rejuvenation**, effectively addressing both **deep volume restoration** and **superficial skin hydration/radiance**. Presented in a **1.0 ml prefilled syringe**, it contains a **high concentration (25 mg/ml) of HA** comprising a unique blend of **cross-linked particles and free, non-cross-linked HA chains**. This biphasic structure allows it to perform dual functions: volumizing and lifting deeper structures while hydrating and smoothing superficial layers. **No integrated lidocaine** necessitates adjunctive anesthesia.https://skin-reboot.com/

**Core Technology & Properties:**
* **Biphasic NASHA Gel:** Combines **cross-linked HA particles** (for structural support and longevity) with **free HA molecules** (for immediate hydration and bio-integration). Cross-linked via BDDE.
* **Dual Rheological Profile:**
* **Medium-High G-Prime (Elasticity/Lift):** The cross-linked particles provide significant lifting capacity and resistance to deformation in mid-to-deep layers.
* **Low Viscosity/Hydration:** The free HA contributes to low viscosity, facilitating superficial placement for hydration and creating a smoother gel feel during injection.
* **Optimized Cohesivity:** Particles exhibit balanced cohesivity, ensuring structural integrity for volume without excessive stiffness, while the free HA enhances spreadability.
* **Particle Size Distribution:** Includes particles suitable for mid-dermal volumization and smaller components effective for superficial hydration.

**Mechanism of Action:**
1. **Immediate Hydration & Radiance:** Free HA binds water instantly upon superficial injection, improving skin texture, elasticity, and luminosity.
2. **Volumization & Structural Support:** Cross-linked HA particles provide lift and replace volume loss in mid-to-deep dermal/subcutaneous planes.
3. **Line & Fold Effacement:** Corrects moderate nasolabial folds, marionette lines, and superficial fine lines via volumizing and hydrating actions.
4. **Biostimulation:** Provides a scaffold for potential collagen/elastin synthesis.
5. **Contour Enhancement:** Augments cheeks, chin, and jawline.

**Primary Indications:**
* **Nasolabial Folds (Mild to Moderate):** Primary fold correction indication.
* **Marionette Lines & Pre-jowl Sulcus:** Addressing oral commissure descent and pre-jowl hollowing.
* **Cheek Augmentation & Volumization:** Restoring midface volume and contour.
* **Skin Quality Improvement & Superficial Hydration:** Enhancing radiance, elasticity, and fine lines in areas like perioral, periorbital, and décolletage via micro-droplet technique.
* **Lip Enhancement (Body & Border):** Adding volume and definition (requires precision).
* **Chin & Jawline Definition:** Improving projection and contour.
* **Dorsal Hand Rejuvenation:** Correcting volume loss and skin quality.

**Key Administration Considerations:**
* **Ready-to-Use:** No reconstitution required.
* **Anesthesia:** **Mandatory adjunctive anesthesia required** (topical, local infiltration, blocks). No integrated lidocaine.
* **Technique:** Versatile based on depth:
* **Needles:** Suitable for sharp needles (27-30G for superficial hydration, 25-27G for volumizing).
* **Cannulas:** Compatible with blunt cannulas (25-27G) for safer placement in folds/lips.
* **Methods:** Linear threading, fanning (mid-to-deep), serial puncture, micro-droplet (superficial), bolus (deep volumizing).
* **Depth:** **Adaptable:**
* *Superficial Dermis:* Micro-droplet technique for skin quality/hydration.
* *Mid-Dermis:* Folds, lips, fine lines.
* *Deep Dermis/Subcutaneous:* Volumizing cheeks, chin, jawline. *Match depth to goal.*
* **Volume:** Moderate volumes. Layering recommended.
* **Post-Treatment:** Swelling, redness, tenderness, bruising possible. Avoid pressure/massage.
* **Longevity:** Typically **9-12 months** (volumizing effects). Hydration effects may diminish sooner (~3-6 months).
* **Safety:** **Critical Risks:** **Vascular occlusion** (especially lips/NLF area – aspirate if using needle, prefer cannula). **Tyndall effect** risk if superficial cross-linked particles are visible (avoid overly superficial placement for volumizing). Risk of **nodules/lumps** with poor technique or overcorrection (especially superficial). Granuloma risk (rare). Lidocaine allergy irrelevant.
* **Regulatory Status:** **CE marked** (Europe/international). **Not FDA-approved in the USA.**
* **Prescription:** Prescription medical device.

Plejuv offers injectors a dual-action biphasic HA solution, combining deep structural support with superficial rejuvenation, demanding careful technique selection to leverage both its volumizing and hydrating properties effectively.CONTACT US